Skip to main content

Table 1 Study population

From: Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial

 

AL only

AL + 0.25 mg/kg PQ

AL + 0.40 mg/kg PQ

Asymptomatic parasite carriers (Study Phase A)

 Female (%)

51.6

52.0

53.4

 Age (years)

7.5 (4 – 10)

8 (5 – 10)

8 (4 – 10)

 Haemoglobin (g/dL) at enrolmenta

10.8 (10.2 – 11.4)

11.3 (10.7 – 11.9)

11.7 (11.2 – 12.2)

 Asexual parasite levels at enrolment (parasites/μL; Microscopy)

2,972.5 (1,147 – 6,865)

2,503 (939 – 5,798)

3,339 (874 – 7,358)

 Gametocyte prevalence (%) at enrolment (Microscopy)

17.7

32.0

20.5

 Gametocyte prevalence (%) at enrolment (QT-NASBA)

96.4

92.9

85.5

Asymptomatic gametocyte carriers (Study Phase B)

 Female (%)

43.1

46.0

42.9

 Age (years)

8 (5 – 11)

7 (6 – 11)

8 (6 – 11)

 Haemoglobin (g/dL) at enrolmenta

11.4 (11.1 – 11.8)

11.7 (11.4 – 12.1)

11.5 (11.1 – 11.9)

 Asexual parasite levels at enrolment (parasites/μL; Microscopy)

488 (226 – 1,670)

957 (248 – 3,004)

908.5 (198 – 2,297)

 Gametocyte prevalence (%) at screening (Microscopy)

100

100

100

 Gametocyte prevalence (%) at enrolment (Microscopy)

69.4

55.3

83.3

 Gametocyte prevalence (%) at enrolment (QT-NASBA)

95.9

93.7

100.0

 Gametocyte levels at enrolment (parasites/μL)b

17.3 (7.2 - 45.1)

18.6 (7.8 - 75.3)

16.6 (7.2 - 40.0)

  1. Means and 95 % confidence intervals are presented for haemoglobin levels at enrolment; medians and interquartile ranges are presented for parasite levels (asexual or sexual stages) and age. Study Phase A = presence of asexual parasites (1,000 - 200,000 parasites/μl) at screening as an inclusion criterion; Study Phase B = presence of patent gametocytes at screening as an inclusion criterion
  2. AL artemether-lumefantrine, PQ primaquine
  3. aMeasured by Hemocue photometer; similar values observed with full blood count assessment using venous samples
  4. bQuantified by qRT-PCR (only children with patent gametocytes on day 0 [N = 150] were included [100/150 were enrolled during Study Phase B]; see Methods)